Sorafenib, a multi-target TKI used in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), inhibits both tumor proliferation and angiogenesis by targeting the VEGF signaling pathway among others [84,85]. The gene discussed is VEGFA; the disease is neoplasm.